- Details
- Christopher Wallis and Zachary Klaassen discuss the publication titled, "The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study." This trial aimed to determine whether the combination of PSMA + MRI was supe...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss a publication entitled, “Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.” This study is investigating how molecular subtypes impact pathological response and survival in patients receiving preoperative cisplatin-based chemotherapy. This study shows that tumor classification by gene expression profiling and...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss the KEYNOTE-057 study. The KEYNOTE-057 study sought to assess whether pembrolizumab could induce the clinical complete response in patients with BCG-unresponsive high-risk NMIBC. Standard treatment for high-risk non-muscle-invasive bladder cancer (NMIBC) is transurethral resection of bladder tumor followed by intravesical Bacillus Calmette-Guerin (BC...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss a Lancet Oncology publication on the KEYNOTE-361 trial, pembrolizumab alone, or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma: A randomized open-label phase three trial. The authors of this trial assessed outcomes with first-line pembrolizumab alone or combined with chemotherapy versus chemothe...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss the CheckMate 274 publication, “Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.” The role of adjuvant treatment in high-risk muscle-invasive urothelial carcinoma after radical surgery is not clear. The authors of this publication assigned patients with muscle-invasive urothelial carcinoma who had undergone radical surgery t...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss a paper entitled, “Randomized Phase 3 Trial of Gemcitabine and Cisplatin with Bevacizumab or Placebo in Patients with Advanced Urothelial Carcinoma.” Currently, the standard of care remains cisplatin-based chemotherapy without the addition of biologic agents. The addition of bevacizumab did not improve overall survival when added to gemcitabine and c...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss the OMNIVORE study published in the Journal of Clinical Oncology. This phase II response-adaptive trial investigated the rational application of immune checkpoint blockade in renal cell carcinoma. Biographies: Christopher J.D. Wallis, MD, Ph.D., Assistant Professor in the Division of Urology at the University of Toronto. Zachary Klaassen, MD, MSc, Ur...
|
- Details
- Zachary Klaassen and Christopher Wallis discuss the abstract "MRI-Targeted or Standard Biopsy in Prostate Cancer Screening," in this UroToday Journal Club. Magnetic resonance imaging (MRI) with targeted biopsy has shown the potential to address the challenge of overdiagnosis in prostate cancer screening. Biographies: Christopher J.D. Wallis, MD, Ph.D., Assistant Professor in the Division of Urolog...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss a publication about 225Actinium PSMA-617 and 177Lutetium PSMA-617 tandem therapy in metastatic castration-resistant prostate cancer (mCRPC) patients who have previously been treated with 177Lutetium PSMA-617 monotherapy. Biographies: Christopher J.D. Wallis, MD, Ph.D., Assistant Professor in the Division of Urology at the University of Toronto. Zacha...
|
- Details
- Christopher Wallis and Zachary Klaassen review the published OLIGOPELVIS GETUG P07 trial, a multicenter phase II trial of combined high-dose salvage radiotherapy and hormone therapy in oligorecurrent pelvic node relapses in prostate cancer. The hypothesis here is that intervention at the time of oligometastatic disease with treatment of these metastatic sites, may actually be curative rather than...
|
